Navigation Links
Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
Date:12/18/2009

d pharmaceutical products or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force, which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 26, 2009 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developmen
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
2. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 ... held a press conference in Taipei ... in its new Vaucarrin™ platform, a targeted drug delivery ... This event was part of a joint ... Gold NanoTech Inc. (GNT), showcasing GNT,s latest edible ...
(Date:9/1/2015)... Sept. 1, 2015   Ivenix Inc. , ... management system, closed on a $42M round of ... Ventures. Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity ... the round. This financing will support the company,s ... Leerink Partners LLC acted as the exclusive placement ...
(Date:9/1/2015)... , Sept. 1, 2015 CytRx Corporation ... development company specializing in oncology, today announced that ... Executive Officer, and David Haen , Vice ... present a corporate overview at two significant investment ... and healthcare industries: the FBR & Co. Second ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4
... - Potential First-in-Class Treatment for Type 2 Diabetes ... Inc., a,biopharmaceutical company focused on the discovery and ... metabolic diseases,announced today that it has dosed the ... clinical trial of MBX-2982, a potential first-in-class treatment,for ...
... 25 ExonHit Therapeutics, a drug,and diagnostic discovery ... 1,study assessing the effects of its lead compound, ... EHT 0202 is a,compound, with a novel mechanism ... and neuronal loss and is currently tested in ...
Cached Medicine Technology:Metabolex Initiates Phase 1 Trial of MBX-2982 2ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans 2ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans 3ExonHit's EHT 0202 Counters Scopolamine's Detrimental Effects on Cognition in Humans 4
(Date:9/1/2015)... ... 2015 , ... Negative pressure wound therapy (NPWT) entails the ... exudates, fluid, and infectious materials to prepare the wound for healing and closure. ... canisters, etc.) is projected to expand continuously through 2021. , Rising patient and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, TX ... , an innovative vaginal health laser procedure that prevents and resolves dryness in ... atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse and ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Screeners (NAPBS®) has announced that Edge Information Management has been granted ... Background Screening Credentialing Council (BSCC). , ÔÇťAchieving and maintaining this accreditation ...
(Date:9/1/2015)... Burlington, MA (PRWEB) , ... September 01, 2015 ... ... for remote real-time monitoring and analysis of pet vital signs and activity, today ... Cornerstone is one of the most popular and widely-adopted veterinary hospital Practice Management ...
(Date:9/1/2015)... ... September 01, 2015 , ... Discovia, ... entities, announced today that it has hired Scott Sanderson, an experienced business development ... capacity, Sanderson will be responsible for establishing and managing new client relationships in ...
Breaking Medicine News(10 mins):Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2
... second year in a row, survivors and generous souls alike ... Thriving Breast Fest Burlesque Show and Auction supporting the You ... burlesque show, silent auction and raffle, will take place on ... Hill,s in SoHo (511 Greenwich Street, NY). , All proceeds ...
... is one of five academic medical centers in the ... the University HealthSystem Consortium (UHC). The prestigious award is ... high-quality care, as measured by the UHC Quality and ... year, 93 member hospitals were ranked by UHC, a ...
... exists, experts say, , FRIDAY, Oct. 2 (HealthDay News) -- ... earlier treatment can begin. On that, experts agree. , ... odds of developing the degenerative brain disorder -- including some ... to figure it out: Do you or don,t you have ...
... Oct. 2 Amicus Therapeutics (Nasdaq: FOLD ) ... open-label study to assess the safety, tolerability and preliminary ... treatment-naive adult patients with type 1 Gaucher disease. ... on/four days off and seven days on/seven days off) ...
... long way in the last decade. Today, one can talk, text ... access the Web. Now imagine a cell phone that can be ... water quality after a major disaster like a hurricane or earthquake. ... at UCLA,s Henry Samueli School of Engineering and Applied Science, has ...
... remarkable history, role of dentists and reaffirms patient advocacy ... (ADA) yearlong observance of its 150th birthday will culminate with ... Waikiki Shell. , "The ADA,s 150th anniversary is a very ... Association," said ADA President John S. Findley, D.D.S. "It ...
Cached Medicine News:Health News:You Can Thrive! Burlesque Show Celebrates the Girls and the Women Who Are Battling to Keep Them 2Health News:University Hospitals Case Medical Center earns prestigious national award for excellence 2Health News:Uncertainty Surrounds Testing for Alzheimer's 2Health News:Uncertainty Surrounds Testing for Alzheimer's 3Health News:Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease 2Health News:Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease 3Health News:Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease 4Health News:Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease 5Health News:NIH recognizes engineering professor's innovative research with major award 2Health News:NIH recognizes engineering professor's innovative research with major award 3Health News:ADA Culminates Yearlong 150th Anniversary Observance at Its 150th Annual Session 2Health News:ADA Culminates Yearlong 150th Anniversary Observance at Its 150th Annual Session 3
The MC-3 allows for simultaneous use of two lamps, with an additional built-in spare....
... a high light intensity. Light ... different brightness steps (Halogen 150) ... output can be adapted to ... small diameter scope, etc.). Different ...
Cold light source single outlet....
Cold light source single outlet....
Medicine Products: